Monograph Details
|
|
Endocrine System
> Diabetes
|
|
GLYNASE PRESTAB |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Sulfonylurea (2nd generation). |
| Generic Name |
|
Glyburide, micronized 1.5mg, 3mg, 6mg; scored tabs. |
| Indications |
|
Adjunct to diet in type 2 diabetes. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 1.5–3mg daily with breakfast. Debilitated: initially 0.75mg daily with breakfast. Increase by 1.5mg at weekly intervals if needed per blood glucose. Maintenance: 0.75–12mg daily in single or divided doses (consider divided doses above 6mg daily); max 12mg daily. |
| Elderly |
|
Initially 0.75mg daily with breakfast. |
| Contraindications |
|
Ketoacidosis. Type 1 diabetes, as sole therapy. |
| Precautions |
|
Impaired renal or hepatic function. Adrenal or pituitary insufficiency. Stress. Secondary failure may occur with extended therapy. Monitor urine and blood glucose. Discontinue if jaundice or persistent rash occurs. Retitrate if transfer from other glyburide containing or hypoglycemic agents (see literature). Malnourished. Elderly. Debilitated. Pregnancy (Cat.B): consider using insulin instead. Nursing mothers: not recommended. |
| Interactions |
|
Potentiated by NSAIDs, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, β-blockers. Antagonized by diuretics, steroids, phenothiazines, thyroid products, phenytoin, niacin, sympathomimetics, calcium channel blockers and isoniazid. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide. |
| Adverse Reactions |
|
Increased risk of cardiovascular mortality. Hypoglycemia, cholestatic jaundice, GI disturbances, allergic skin reactions, photosensitivity, blood dyscrasias, hepatic porphyria. |
| How Supplied |
PresTab 1.5mg—100
3mg—100, 500, 1000
6mg—100, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
